GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

REMD-477

Company
University of California, San Diego
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for REMD-477 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07212868

    The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery

    Not yet reported The University of Texas Health Science Center at San Antonio 150 participants Est. completion 2030-06-30 2 sites Stand-alone
    Other conditions: Non-Diabetic
    View official trial listing →
  • Completed NCT NCT02455011

    Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus

    Not yet reported, Not yet reported REMD Biotherapeutics, Inc. 75 participants Est. completion 2018-02 3 sites Stand-alone
    Type 2 diabetes Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT02715193

    Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

    Not yet reported REMD Biotherapeutics, Inc. 21 participants Est. completion 2017-01 2 sites Stand-alone
    Other conditions: Type 1 Diabetes Mellitus, Diabetes
    View official trial listing →
  • Completed NCT NCT03117998

    Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus

    Not yet reported REMD Biotherapeutics, Inc. 154 participants Est. completion 2021-03-05 11 sites Stand-alone
    Other conditions: Type1 Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT03919617

    Metabolic Pathways of GRA in Patients With Type 1 Diabetes

    Not yet reported, Not yet reported University of California, San Diego 4 participants Est. completion 2022-05-31 1 site Stand-alone
    Other conditions: Type 1 Diabetes Mellitus
    View official trial listing →
  • Terminated NCT NCT04253223

    A Study to Determine Safety and Efficacy of (REMD-477) in Controlling Hyperglycemia Due to Copanlisib

    Not yet reported Duke University 1 participants Est. completion 2021-05-05 1 site Stand-alone
    Other conditions: Hyperglycemia Drug Induced
    View official trial listing →
  • Terminated NCT NCT04330625

    Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)

    Not yet reported Duke University 1 participants Est. completion 2021-05-05 1 site Stand-alone
    Other conditions: Hyperglycemia Drug Induced
    View official trial listing →
  • Completed NCT NCT04545411

    Combination GRA and SGLT-2i Treatment in Type 1 Diabetes

    Not yet reported, Not yet reported University of California, San Diego 12 participants Est. completion 2022-10-31 1 site
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Active, not recruiting NCT NCT04779645

    Effects of GRA in Patients With Type 1

    Not yet reported University of California, San Diego 30 participants Est. completion 2025-12-31 1 site Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT05093517

    Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

    Not yet reported The University of Texas Health Science Center at San Antonio 4 participants Est. completion 2022-03-16 1 site Stand-alone
    Type 2 diabetes Other conditions: Glucose Tolerance Impaired, Insulin Sensitivity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.